Table 3

Associations of breast cancer with IGF-I, IGF-II, and IGFBP-3 in all women

Variable	Number	Unadjusted			Number	Adjusted^a			Adjusted^b
Variable		Case/control	OR	95% CI	Case/control	OR	95% CI	OR	95% CI
IGF-I (ng/ml)
Continuous
ln (IGF-I)	299/300	2.47 (P < 0.001)	1.45–4.22	283/291	2.23 (P = 0.007)	1.25–3.99	1.46 (P = 0.279)	0.73–2.92
Categorical (by tertile)
≤107.5	77/98	1.00		72/96	1.00		1.00
107.5–149.6	89/101	1.18	0.75–1.85	86/98	1.33	0.82–2.14	1.16	0.71–1.92
≥149.6	133/101	2.01	1.26–3.19	125/97	1.95	1.18–3.23	1.49	0.85–2.59
Trend test		P = 0.003			P = 0.009		P = 0.199
IGF-II (ng/ml)
Continuous
ln (IGF-II)	299/300	2.51 (P = 0.050)	1.00–6.31	283/291	1.76 (P = 0.280)	0.63–4.88
Categorical (by tertile)
≤711.6	95/99	1.00		92/94	1.00
711.6–945.1	91/100	1.06	0.66–1.70	86/98	1.00	0.59–1.69
≥945.1	113/101	1.54	0.79–2.97	105/99	1.22	0.58–2.57
Trend test		P = 0.214			P = 0.613
IGFBP-3 (ng/ml)
Continuous
ln (IGFBP-3)	299/300	5.27 (P < 0.001)	2.34–11.88	283/291	4.31 (P < 0.001)	1.80–10.31	3.15 (P = 0.029)	1.12–8.82
Categorical (by tertile)
≤3698	65/99	1.00		62/96	1.00		1.00
3698–4395	92/99	1.46	0.95–2.23	88/96	1.28	0.81–2.04	1.16	0.71–1.88
≥4395	142/102	3.01	1.81–4.99	133/99	3.00	1.70–5.31	2.50	1.37–4.58
Trend test		P < 0.001			P < 0.001		P = 0.004

^a Adjusted for BMI, age at menarche, age at first live birth, total energy intake, WHR, history of fibroadenoma, and family history of breast cancer.
^b Adjusted for BMI, age at menarche, age at first live birth, total energy intake, WHR, history of fibroadenoma, family history of breast cancer, and either IGFBP-3 or IGF-I.